The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands
Open accessAbstract
Objective: To investigate the incidence and characteristics of breast cancer in transgender people in the Netherlands compared with the general Dutch population. Design: Retrospective, nationwide cohort study. Setting: Specialised tertiary gender clinic in Amsterdam, the Netherlands. Participants: 2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth, male gender identity) who received gender affirming hormone treatment. Main outcome measures: Incidence and characteristics (eg, histology, hormone receptor status) of breast cancer in transgender people. Results: The total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast cancer were identified (median duration of hormone treatment 18 years, range 7-37 years). This was 46-fold higher than in cisgender men (standardised incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). Most tumours were of ductal origin and oestrogen and progesterone receptor positive, and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four cases of invasive breast cancer were identified (median duration of hormone treatment 15 years, range 2-17 years). This was lower than expected compared with cisgender women (standardised incidence ratio 0.2, 95% confidence interval 0.1 to 0.5). Conclusions: This study showed an increased risk of breast cancer in trans women compared with cisgender men, and a lower risk in trans men compared with cisgender women. In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern. These results suggest that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Coleman, E., Bockting, W., Botzer, M., Cohen-Kettenis, P., DeCuypere, G., Feldman, J., Fraser, L., Green, J., Knudson, G., Meyer, W. J., et al. (2012) · International Journal of Transgenderism · doi:10.1080/15532739.2011.700873 · Cited by 3,143
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Casparie, M., Tiebosch, A. T. M. G., Burger, G., Blauwgeers, H., van de Pol, A., van Krieken, J. H. J. M., & Meijer, G. A. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/971816 · Cited by 882
Wiepjes, C. M., Nota, N. M., de Blok, C. J. M., Klaver, M., de Vries, A. L. C., Wensing-Kruger, S. A., de Jongh, R. T., Bouman, M.-B., Steensma, T. D., Cohen-Kettenis, P., et al. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.01.016 · Cited by 571
Self-citationEarly Detection and Screening for Breast Cancer
Coleman, C. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.02.009 · Cited by 281
Grynberg, M., Fanchin, R., Dubost, G., Colau, J.-C., Brémont-Weil, C., Frydman, R., & Ayoubi, J.-M. (2010) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2009.12.021 · Cited by 256
Breast Cancer Development in Transsexual Subjects Receiving Cross-Sex Hormone Treatment
Gooren, L. J., van Trotsenburg, M. A. A., Giltay, E. J., & van Diest, P. J. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12319 · Cited by 245
Cited by
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 587
Daly, M. B., Pal, T., Maxwell, K. N., Churpek, J., Kohlmann, W., AlHilli, Z., Arun, B., Buys, S. S., Cheng, H., Domchek, S. M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0051 · Cited by 315
Management of Male Breast Cancer: ASCO Guideline
Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., Roshal, A., Ruddy, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03120 · Cited by 263
Metadata
- Authors
- de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbé, E., Konings, I. R. H. M., & den Heijer, M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-05-14
- Volume
- 365
- Pages
- l1652
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2945602723
- Cited by
- 366
- References
- 27
- FWCI
- 46.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. https://app.cochat.ai/papers/10.1136/bmj.l1652
- The paper
- de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbé, E., Konings, I. R. H. M., & den Heijer, M. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. https://doi.org/10.1136/bmj.l1652
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.